Dendreon Corporation Announces Completion of $150 Million Common Stock Offering.Business Editors & Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--Feb. 4, 2004 Dendreon Corporation (Nasdaq:DNDN) today announced that the underwriters of its recent public offering of 10,250,000 shares of common stock have purchased 1,514,705 additional shares pursuant to the exercise of their over-allotment option in full, resulting in total gross proceeds to Dendreon of approximately $150 million in this offering. UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Securities LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control acted as the sole book-running manager in the offering. Needham & Company, Inc., Piper Jaffray & Co. and Lazard Freres & Co. LLC acted as co-managers. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities. This offering of shares of common stock was made only by means of a prospectus supplement and accompanying prospectus. A copy of the final prospectus Final Prospectus A legal document stating the price of a newly issued security, the delivery date, and other facts that are important for investors. Notes: The final prospectus must be given to every investor who purchases a new issue of registered securities. supplement and accompanying prospectus can be obtained from: UBS Securities LLC, 299 Park Avenue, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY 10171. Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The company's lead investigational product candidate, Provenge(R), is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for the treatment of androgen androgen (ăn`drəjən): see testosterone. androgen Any of a group of hormones that mainly influence the development of the male reproductive system. independent prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing , small molecule and pro-drug product candidates. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may affect Dendreon's ability to discover, develop and commercialize drugs that are safe and effective for use as human therapeutics include risks related to Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials of Provenge and other product candidates, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk that the Food and Drug Administration will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, the uncertainty of Dendreon's future access to capital, and dependence on intellectual property. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion